相关实验视频

Updated: Sep 18, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在三阴性乳腺癌 (NeoSACT) 中新辅助性anlotinib/sintilimab加化疗:第二阶段试验

Liulu Zhang¹, Lu Yang², Yan Ge³

¹Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Cell reports. Medicine

|June 20, 2025

概括

新辅助剂安洛提尼布,辛蒂利马布和化疗显示,三阴性乳腺癌 (TNBC) 的病理完整反应 (pCR) 率高. 这种组合治疗,包括PD-L1阴性患者,提供了有前途的无事件生存.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

瘤血管生成促进免疫逃避,阻碍有效的癌症治疗.
血管正常化可以通过修改瘤微环境来改善免疫治疗结果.
三重阴性乳腺癌 (TNBC) 存在重大治疗挑战.

研究的目的:

评估新辅助性安洛提尼布,辛提利马布和化疗在II-III期TNBC中的疗效.
评估病态完整响应 (pCR) 和最小残留疾病 (RCB 0+1) 率.
分析基于编程死亡连接体1 (PD-L1) 表达的治疗结果.

主要方法:

第二阶段临床试验涉及29名II-III期TNBC患者.
组合疗法包括安洛提尼布 (抗血管),辛提利马布 (PD-1 抑制剂) 和化疗.
主要终点:病理完整反应 (pCR). 二级终点包括残留癌症负担 (RCB) 和无事件生存率 (EFS).

主要成果:

达到了69.0%的pCR率,其中86.2%的患者显示最小残留疾病 (RCB 0+1).
PD-L1阴性患者的pCR率 (75.0%) 与PD-L1阳性患者 (64.7%) 的pCR率相当.
两年无事件生存率 (EFS) 为92.4%,在获得PCR的患者中达到100%.

结论:

将抗血管原治疗与免疫疗法和化疗相结合,可显著提高高风险TNBC的治疗疗效.
这种组合策略可以克服与PD-L1表达状态相关的限制.
根据这些有希望的结果,对高风险的TNBC进行进一步调查是有必要的.

关键词:

抗血管生成是一种反血管生成.免疫检查点抑制剂免疫检查点抑制剂新辅助疗法是一种新辅助疗法.病态的完整反应.三重阴性乳腺癌是什么

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...